Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

The Latest Pharma Jobs, News and Events

pharmiweb.com today | 28 August 2014

ViiV Healthcare receives FDA approval for Triumeq®

ViiV Healthcare has announced that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. Triumeq is ViiV Healthcare’s first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen  that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine....

Commenting on Friday 22nd August, Dr Dominique Limet, Chief Executive Officer, ViiV Healthcare, said: “Today’s approval of Triumeq offers many people living with HIV in the US the first single-pill regimen containing dolutegravir. ViiV Healthcare is committed to delivering advances in care and new treatment options to physicians and people living with HIV. We are proud to announce this important milestone, marking the second new treatment to be approved in the US from our pipeline of medicines.”

show more

Latest Poll

Would you ever take part in a Clinical Trial?

Yes 40% 40%
Possibly 24% 24%
Probably not 22% 22%
Never 14% 14%
Advertising

Content

PharmiWeb.com is a product of PharmiWeb Solutions - a global provider of digital solutions for the pharmaceutical sector.

We increase engagement with healthcare professionals, patients, carers and consumers, through:

Click here to go to learn more about us.

Pharmiweb Solutions